TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Sutro Biopharma ( (STRO) ) is now available.
On December 2, 2025, Sutro Biopharma announced a 1-for-10 reverse stock split of its common stock, effective December 3, 2025, to comply with Nasdaq’s minimum bid price requirement. This move, approved by the Board on November 20, 2025, reduces the number of outstanding shares from approximately 85 million to 8.5 million, with no change to stockholder ownership percentages except for rounding up fractional shares.
The most recent analyst rating on (STRO) stock is a Sell with a $7.00 price target. To see the full list of analyst forecasts on Sutro Biopharma stock, see the STRO Stock Forecast page.
Spark’s Take on STRO Stock
According to Spark, TipRanks’ AI Analyst, STRO is a Underperform.
Sutro Biopharma’s overall stock score is primarily impacted by its financial performance challenges, including negative equity and cash flow issues. The technical analysis indicates a bearish trend, while the valuation is weak due to the negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall score.
To see Spark’s full report on STRO stock, click here.
More about Sutro Biopharma
Sutro Biopharma, Inc. is a clinical-stage oncology company focused on developing next-generation antibody-drug conjugates (ADCs) that are designed to deliver single- and dual-payload ADCs. These innovations aim to improve drug exposure, reduce side effects, and expand the range of treatable tumor types, targeting large oncology markets with significant need for improved therapies.
Average Trading Volume: 98,728
Technical Sentiment Signal: Strong Sell
Current Market Cap: $68.24M
For detailed information about STRO stock, go to TipRanks’ Stock Analysis page.